Arcutis Biotherapeutics, Inc. Stock

Equities

ARQT

US03969K1088

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
9.45 USD -7.80% Intraday chart for Arcutis Biotherapeutics, Inc. -20.45% +192.57%
Sales 2024 * 106M Sales 2025 * 220M Capitalization 1.09B
Net income 2024 * -241M Net income 2025 * -164M EV / Sales 2024 * 8.05 x
Net cash position 2024 * 231M Net cash position 2025 * 228M EV / Sales 2025 * 3.9 x
P/E ratio 2024 *
-4.03 x
P/E ratio 2025 *
-6.17 x
Employees 296
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.5%
More Fundamentals * Assessed data
Dynamic Chart
Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes CI
Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index CI
Arcutis Promotes Todd Tucker to Chief Human Resources Officer CI
Arcutis Biotherapeutics Says Atopic Dermatitis Cream Met Primary Endpoint in Phase 3 Study in Children MT
Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting CI
Arcutis Biotherapeutics Raises $172.5 Million in Common Stock Offering MT
Arcutis Plans $150 Million Offering, Signs Collaboration, Licensing Deal for Roflumilast in Japan; Shares Fall After Hours MT
Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating MT
Needham Raises Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating MT
Transcript : Arcutis Biotherapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024
North American Morning Briefing : Stock Futures Pause as Investors Eye Inflation Data DJ
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q4 Revenue $13.5M, vs. Street Est of $11.4M MT
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Mizuho Increases Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating MT
Arcutis Biotherapeutics, Inc. Announces Publication of Positive Results from the Pivotal Phase 3 Trial Evaluating ZORYVE (roflumilast) Foam CI
More news
1 day-7.80%
1 week-20.45%
Current month-4.64%
1 month-7.67%
3 months+188.99%
6 months+192.57%
Current year+192.57%
More quotes
1 week
9.31
Extreme 9.31
10.47
1 month
9.09
Extreme 9.09
13.17
Current year
3.07
Extreme 3.07
13.17
1 year
1.76
Extreme 1.76
15.21
3 years
1.76
Extreme 1.76
36.45
5 years
1.76
Extreme 1.76
40.88
10 years
1.76
Extreme 1.76
40.88
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 15-12-31
Chief Tech/Sci/R&D Officer - 21-05-31
Chief Operating Officer - 20-05-26
Members of the board TitleAgeSince
Chairman 53 16-03-31
Founder 69 16-05-31
Director/Board Member 62 21-09-01
More insiders
Date Price Change Volume
24-04-18 9.45 -7.80% 2,918,549
24-04-17 10.25 +1.49% 2,515,933
24-04-16 10.1 +0.10% 1,859,563
24-04-15 10.09 -1.08% 2,688,210
24-04-12 10.2 -14.14% 4,161,247

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.25 USD
Average target price
18 USD
Spread / Average Target
+75.61%
Consensus